surmount-1 trial tirzepatide obesity without diabetes once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Clinical trials of subcutaneous tirzepatide

Who Is a Good Candidate for Treatment

1, 2024 from US Food & Drug Administration (FDA-a)

The 12-week rotation protocol Week 1: Right abdomen, upper quadrant (above navel, right side) Week 2: Left abdomen, upper quadrant (above navel, left side) Week 3: Right anterior thigh, upper portion Week 4: Right abdomen, lower quadrant (below navel, right side) Week 5: Left abdomen, lower quadrant (below navel, left side) Week 6: Left anterior thigh, upper portion Week 7: Right abdomen, lateral (right side, toward hip) Week 8: Left abdomen, lateral (left side, toward hip) Week 9: Right anterior thigh, lower portion Week 10: Right upper arm (if partner available) or right abdomen central Week 11: Left anterior thigh, lower portion Week 12: Left upper arm (if partner available) or left abdomen central After week 12, restart the cycle

The result is fewer cravings and smaller portions feeling enough, which makes the lifestyle side of weight loss much more manageable

These mechanisms are not mutually exclusive, and in practice, dizziness during retatrutide treatment may reflect a combination of contributing factors rather than a single cause